DMARDs are a medication that suppresses the immune system. People may take them to slow disease progression in autoimmune or inflammatory conditions, such as different types of arthritis. Inflammation ...
The use of newer biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) for treating juvenile idiopathic arthritis (JIA) rose sharply from 2001 to 2022, while the use of ...
Since their first publication in 2010, the EULAR recommendations for the use of disease-modifying anti-rheumatic treatments (DMARDs) in people with RA have become a most important publication in the ...
Patients with Medicare Part D insurance plans experience uneven and “restrictive” coverage of certain drugs and drug classes ...
Autoimmune rheumatic diseases commonly affect individuals of childbearing age, with historically increased adverse pregnancy outcomes in this group. The advent of disease-modifying antirheumatic drugs ...
Early diagnosis leads to earlier treatment. With earlier treatment of rheumatoid arthritis (RA), there is a better chance for less radiographic damage, less disability and thus lower overall costs of ...
After the first 6 months of disease-modifying antirheumatic drugs (DMARDs) use in patients with rheumatoid arthritis (RA), most very abnormal results newly seen in long-term routine laboratory ...
A scoping review published in Arthritis Care & Research compares existing recommendations for the use of disease-modifying anti-rheumatic drugs (DMARDs) in pregnancy and reproductive health for women ...
Managing symptoms of rheumatoid arthritis may require trying different medicines to see what works best for you and your symptoms. The approval of Xeljanz has led to changes in how rheumatoid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results